Kingsview Wealth Management LLC Has $12.60 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Kingsview Wealth Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 46.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 75,976 shares of the company's stock after selling 66,389 shares during the period. Kingsview Wealth Management LLC's holdings in Johnson & Johnson were worth $12,600,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $29,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $0.67 during mid-day trading on Friday, hitting $163.65. The company's stock had a trading volume of 9,764,459 shares, compared to its average volume of 8,138,164. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a market capitalization of $393.75 billion, a PE ratio of 17.50, a price-to-earnings-growth ratio of 2.18 and a beta of 0.41. The stock's 50-day moving average is $154.10 and its two-hundred day moving average is $154.84.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business earned $2.82 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.18%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday. Morgan Stanley increased their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday. Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday. UBS Group restated a "buy" rating and issued a $190.00 price objective (up previously from $180.00) on shares of Johnson & Johnson in a report on Thursday. Finally, Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $174.11.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.